Overview

Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

Status:
Completed

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

A Phase I open-label study to evaluate the pharmacokinetics (what the body does to a drug), safety and tolerability of a single dose of Sativex (containing 10.8 mg tetrahydrocannabinol [THC] and 10 mg cannabidiol [CBD]) in healthy patients and those with hepatic (liver) function impairment.

Phase:

Phase 1

Details

Lead Sponsor:

GW Pharmaceuticals Ltd.

Treatments:

Nabiximols